Progenics Pharmaceuticals, INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$6.8Mgeneral payments (2019-2025)
$22Kresearch payments (2019-2025)
8,991clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| April Teitelbaum | San Diego, CA | Medical Oncology | $1,084,723.09 |
| Gary Ulaner | Los Angeles, CA | Diagnostic Radiology | $469,475.55 |
| Stuart Apfel | West Hempstead, NY | Neurology (Psychiatry & Neurology) | $462,868.75 |
| Steven Rowe | Dallas, TX | Diagnostic Radiology | $371,038.70 |
| Edward Obedian | Oyster Bay, NY | Radiation Oncology | $366,068.94 |
| Medhat Osman | St Louis, MO | Nuclear Medicine | $322,009.72 |
| Daniel Appelbaum | Chicago, IL | Nuclear Radiology | $252,757.87 |
| Tony Abraham | Port Jefferson Station, NY | Nuclear Radiology | $235,989.96 |
| Giuseppe Esposito | Washington, DC | Nuclear Medicine | $231,832.99 |
| Hossein Jadvar | Los Angeles, CA | Nuclear Medicine | $196,463.96 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.